Molecularly, GBM-N019 treatment and the combined regimen resulted in the decreased expressions of mTOR, mTORC1(Raptor), mTORC2 (Rictor), PI3K, STAT3, NFkB, Akt, and CDK6; while the combined treatment negatively impacted the expression level of these oncogenic markers to a greater extent (Figure 8D). The gene discussed is CDK6; the disease is glioblastoma.